- Investor's Business Daily•7 hours ago
Biotech stocks have nearly "round-tripped" their Donald Trump-inspired rally.
- Investopedia•9 hours ago
Regeneron and Sanofi’s eczema drug makes progress toward being marketed in Europe.
- Reuters•22 hours ago
The European Medicines Agency (EMA), the European Union's health regulator, has accepted for review the Dupixent product being developed by drugmakers Sanofi and Regeneron, the companies said on Thursday. Dupixent is aimed at adults with eczema or moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy. If cleared by regulators, Dupixent would be the first approved systemic treatment for eczema, which in severe cases produces infection-prone rashes and a constant itch as bad as poison ivy.
SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||39.72 x 200|
|Ask||39.82 x 200|
|Day's Range||39.54 - 39.92|
|52 Week Range||36.81 - 44.50|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||23.12|
|Dividend & Yield||1.66 (4.07%)|
|1y Target Est||N/A|